| 注册
首页|期刊导航|中国临床药理学杂志|他克莫司与霉酚酸联用的药物不良反应分析

他克莫司与霉酚酸联用的药物不良反应分析

陈鸿圣 刘爽 赵荣生

中国临床药理学杂志2024,Vol.40Issue(19):2896-2900,5.
中国临床药理学杂志2024,Vol.40Issue(19):2896-2900,5.DOI:10.13699/j.cnki.1001-6821.2024.19.027

他克莫司与霉酚酸联用的药物不良反应分析

Analysis of adverse drug reactions induced by tacrolimus combined with mycophenolic acid

陈鸿圣 1刘爽 2赵荣生2

作者信息

  • 1. 北京大学第三医院药学部,北京 100191||北京大学医学部药物评价中心,北京 100191||北京大学药学院药事管理与临床药学系,北京 100191
  • 2. 北京大学第三医院药学部,北京 100191||北京大学医学部药物评价中心,北京 100191
  • 折叠

摘要

Abstract

Objective To mine and analyze the adverse drug reaction(ADR)signals caused by tacrolimus(Tac)combined with mycophenolic acid(MPA)based on Food and Drug Administration(FDA)adverse event reporting system(FAERS)database,so as to provide reference for clinical drug combination.Methods Open Vigil 2.1 platform was used to collect adverse events reports related to Tac and MPA between the first quarter of 2004 and the first quarter of 2023.Disproportionality analysis methods were used to mine the ADR risk signals.Characteristics of the population reporting adverse events were analyzed.ADR that arose from the combination of the two drugs were compared with those specified in the instructions of the two drugs in order to screen out new ADR.Results A total of 32 866 ADR reports of Tac and MPA used in combination were retrieved,in which 17 455 cases(53.11%)were males,11 445 cases(34.82%)were females.Cases were major in age from 40 to 65 years old(13 174 cases,40.08%).ADR with high frequency mainly included pyrexia,infections and renal impairment;ADR with strong signal strength mainly included infections and skin toxicity;new ADR mainly included blood parathyroid hormone increased,heart valve incompetence and acute psychosis.Conclusion When using Tac and MPA in combination,attention and care should be paid to the high frequency,strong signal strength and new signal of ADR.

关键词

他克莫司/霉酚酸/药物不良反应/信号挖掘

Key words

tacrolimus/mycophenolic acid/adverse drug reaction/signal mining

分类

医药卫生

引用本文复制引用

陈鸿圣,刘爽,赵荣生..他克莫司与霉酚酸联用的药物不良反应分析[J].中国临床药理学杂志,2024,40(19):2896-2900,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文